Wockhardt Ltd

Stage 2 · Advancing · week 4Setup 5.1 ★ FairStrong +5.8

As of 9 Oct 2026, Wockhardt is in Stage 2 — advancing, the uptrend phase, in week 4 (since 11 Sep 2026). It closed at ₹1,996, 14.3% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. More about the company

₹1,996.4
-1.64% today
₹32,440 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

Early entry — still early enough in its move

Setup score

5.1 ★ Fair

Momentum

Steady

Edge

Strong +5.8

Setup-score rank among Stage 2 peers: #33 of 61 in Pharmaceuticals · #39 of 78 in Health Care

Is WOCKPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-14.3%
₹1,100.3 lo₹2,329.7 hi
14.3% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 4
1w13w26w
Week 4 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
19.5%
200 DMA: ₹1,670.6 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.70x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +2.3% vs MA50 +5.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-10.2%
3M
+10.3%
6M
+47.9%
YTD
+38.2%
1Y
+33.7%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #34 of 74 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #29 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 28w
S2 36w
S2 14w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 11w → S3 5w → S2 28w → S3 4w → S2 36w → S3 13w → S2 13w → S3 7w → S4 12w → S1 9w → S4 8w → S1 3w → S2 14w → S3 1w → S2 4w current
Total tracked: 169 weeks across 16 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-09-11
4 appearances in last 60 days. First seen: 2024-06-26.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 4 · Vol 0.70x
2026-10-08S2
Wk 4 · Vol 0.79x
2026-10-07S2
Wk 4 · Vol 0.48x
2026-10-06S2
Wk 4 · Vol 0.93x
2026-10-05S2
Wk 3 · Vol 0.84x
2026-10-01S2
Wk 3 · Vol 0.82x
2026-09-30S2
Wk 3 · Vol 0.87x
2026-09-29S2
Wk 3 · Vol 1.36x
2026-09-28S2
Wk 3 · Vol 0.69x
2026-09-25S2
Wk 2 · Vol 0.74x
2026-09-24S2
Wk 2 · Vol 0.88x
2026-09-23S2
Wk 2 · Vol 4.37x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹2,032.6
200 DMA
₹1,670.6
52W High
₹2,329.7
52W Low
₹1,100.3
5D Low
₹1,996.4
Resistance levels (recent highs)
20d High
₹2,329.7
60d High
₹2,329.7
120d High
₹2,329.7
250d High
₹2,329.7
Next resistance
+16.7%
to 20d High
Ask the Market AI about WOCKPHARMAAsk →
P/E (TTM)
135.3
Forward —
ROE
+4.0%
Profit margin +6.3%
About this companyHealth Care· Pharmaceuticals

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.